secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-09-28T12:46:22+00:00
Accession:  0001178913-26-004628
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Silexion reports positive preclinical findings for SIL204 showing lipoprotein-mediated uptake in KRAS-driven cancers
--------------------------------------------------------------------------------

- SIL204 produced robust, dose-dependent mutant KRAS gene silencing in carrier-free assays; serum lipid depletion significantly reduced knockdown efficiency (P < 0.001).
- Exogenous human LDL did not alter silencing potency versus complete serum alone, indicating physiological lipoprotein levels suffice without artificial nanoparticles.
- CSDO Mitchell Shirvan cited LDL receptor upregulation in cancer cells; CEO Ilan Hadar highlighted the Phase 2/3 pancreatic program and systemic subcutaneous delivery.
- Silexion is advancing SIL204 through Phase 2/3 in locally advanced pancreatic cancer, with site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/0001178913-26-004628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/zk2636165.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer